Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02817802
Other study ID # C1503
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date August 2016
Est. completion date October 2025

Study information

Verified date February 2023
Source Biotronik AG
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The registry will investigate the clinical performance and long-term safety of Magmaris in a real world setting


Description:

Coronary stents are the default devices for the treatment of coronary artery disease in percutaneous coronary intervention (PCI) according to existing guidelines. However, thrombosis and restenosis are still the main limitations of current permanent metallic stents. In contrast to Bare Metal Stents (BMSs), Drug Eluting Stents (DESs) have a reduced restenosis rate due to the presence of antiproliferative agents in the coating layer of the stent surface and reduced rate of repeat revascularisation. However, late and very late stent thrombosis remains the limitation of DES in spite of prolonged dual antiplatelet therapy.Bioabsorbable scaffolds have been introduced to overcome limitations of permanent metallic stents. The aim of this observational registry is to investigate the clinical performance and long-term safety of Magmaris in a real world setting.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2066
Est. completion date October 2025
Est. primary completion date July 14, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion cirteria 1. Subject is =18 years of Age 2. Subject must be willing to sign a Patient Informed Consent (PIC) or Patient Data Release Form (PDRF) where applicable 3. Symptomatic coronary artery disease 4. Subject with a maximum of two single de novo lesions in two different major epicardial vessels 5. Target lesion length =21 mm by QCA or by visual estimation 6. Target lesion stenosis by visual estimation: >50% - <100% and TIMI flow =1 7. Subject is eligible for Dual Anti Platelet Therapy (DAPT) 8. Reference vessel diameter between 2.7-3.7 mm by visual estimation, depending on the scaffold size used Exclusion criteria 1. Pregnant and/or breast feeding females or females who intend to become pregnant during the time of the registry 2. Known allergies to: Acetylsalicylic Acid (ASA), clopidogrel, ticlopidin, heparin or any other anticoagulant/antiplatelet required for PCI, contrast medium, sirolimus, or similar drugs; or the scaffold materials including Magnesium, Yttrium, Neodymium, Zirconium,Gadolinium, Dysprosium, Tantalum that cannot beadequately pre-medicated 3. Subjects on dialysis 4. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST Elevation myocardial infarction (STEMI) within 72 hours prior to the index procedure. Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment 5. Documented left ventricular ejection fraction (LVEF) <30% 6. Restenotic target lesion 7. Thrombus in target vessel 8. Target lesion is located in or supplied by a diseased (defined as vessel irregularity per angiogram and >20% stenosed lesion by visual estimation) arterial or venous bypass graft 9. Left main coronary artery disease 10. Ostial target lesion (within 5.0 mm of vessel origin) 11. Target lesion involves a side branch =2.0 mm in Diameter 12. Target vessel (including side branches) has second lesion which requires treatment according to the investigator's discretion 13. Unsuccessful pre-dilatation, defined as residual Stenosis rate more than 20% measured by QCA and / or angiographic complications (e.g. distal embolization, side branch closure, extensive dissections) 14. Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained 15. Currently participating in another study and Primary endpoint is not reached yet. 16. Planned interventional treatment of any target or nontarget vessel Participating Countries Australia, Austria, Belgium, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Latvia, Malaysia, New Zealand, Poland, Portugal, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, United Kingdom

Study Design


Intervention

Device:
Magmaris
PCI (Magmaris)

Locations

Country Name City State
Belgium ZNA Middelheim Cardiologiy Antwerpen
Hong Kong Queen Elizabeth Hospital Kowloon

Sponsors (1)

Lead Sponsor Collaborator
Biotronik AG

Countries where clinical trial is conducted

Belgium,  Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Target Lesion Failure (TLF)* at 12 months 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A

External Links